Extracellular vesicles (EVs) carry diverse bioactive components including nucleic acids,
proteins, lipids and metabolites that play versatile roles in intercellular and interorgan …

In spite of the recent approval of new promising targeted therapies, the clinical outcome of
patients with acute myeloid leukemia (AML) remains suboptimal, prompting the search for …

Background Phenotypic characterization of immune cells in the bone marrow (BM) of
patients with acute myeloid leukemia (AML) is lacking. Methods T‐cell infiltration was …

Relapse after conventional chemotherapy remains a major problem in patients with myeloid
malignancies such as acute myeloid leukemia (AML), and the major cause of death after …

Somatic gene mutations are key determinants of outcome in patients with myelodysplastic
syndromes (MDS) and secondary AML (sAML). In particular, patients with TP53 mutations …

Hematological malignancies possess a distinctive immunologic microenvironment
compared with solid tumors. Here, using an established computational algorithm …

Abstract Exosomes, small (30–150 nm) extracellular vesicles (EVs) isolated from plasma of
patients with acute myeloid leukemia (AML) carry leukemia-associated antigens and …

CD4+ Foxp3+ T regulatory (Treg) cells control many facets of immune responses ranging
from autoimmune diseases, to inflammatory conditions, and cancer in an attempt to maintain …

Abstract Exosomes are small (30–150 nm) membranous vesicles of endocytic origin
produced by all cells under physiological and pathological conditions. They have recently …

In the tumour microenvironment, cancer cells directly interact with both the immune system
and the stroma. It is firmly established that the immune system, historically believed to be a …